IMUGENE LIMITED — Interim / Quarterly Report 2011

Jul 28, 2011

==> picture [533 x 94] intentionally omitted <==

QUARTERLY SHAREHOLDER UPDATE July 2011

Imugene Limited (ASX Code: IMU) specialises in the development and commercialisation of novel animal health products for pigs and poultry. Our range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock.

Imugene finished the 30 June 2011 quarter maintaining the $1.9 million in cash reserves held at the end of the previous quarter, as detailed in the Appendix 4C released today.

Quarter Highlights

• Technology and material transfer programs near completion

• US site visit completed

Technology and Material Transfer

During the quarter ended 30 June 2011, the technology and material transfer programs progressed towards completion with further shipments of vaccine material and cell lines to the US. This is in line with expected timelines. The material transfer process has gone smoothly and only a few non urgent shipments remain.

Imugene Laboratory Work Program

Work at Imugene’s laboratory facility at La Trobe University continued with the updating and expansion of our product range. This included the roll out of our recent product improvements through the entire range of our vaccines and the development of specific vaccines for global regions such as Europe.

Visit to US Laboratory and test site

During the quarter, Dr Warwick Lamb, CEO of Imugene visited the licensee’s facilities. Dr Lamb said, “I am very pleased with the level of expertise that has been applied to our portfolio and am impressed with the progress made so far.

END

ABN 99 009 179 551

Registered Office Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000 Tel +61 8 9440 2660 Fax +61 8 9440 2699

www.imugene.com

Quarterly Shareholder Update – July 2011

==> picture [81 x 30] intentionally omitted <==

For more information please visit the Imugene Website www.imugene.com or contact:

Dr Warwick Lamb Kyahn Williamson Managing Director Investor Relations +61 2 9870 7330 Buchan Consulting +61 (0) 40 1018 828

About Imugene

Imugene Limited (ASX:IMU) specialises in the development of animal health products for pigs and poultry, including vaccines and productivity enhancers.

These biologically-based vaccines:

• Improve the health and welfare of pigs and poultry

• Reduce or eliminate the use of antibiotics, chemicals and drugs, and;

• Result in economic gains for the industries that use them.

Imugene's product portfolio targets a worldwide US$3 billion animal health market and contains vaccines at each stage of the development process.

Constructed using Imugene’s patented Porcine and Fowl Adenoviral Vector Delivery Systems, these vaccines address some of the major diseases and health issues threatening pig and poultry production worldwide, such as Porcine Reproductive and Respiratory Syndrome (PRRS), which causes losses of up to US$1 billion every year.

Imugene has a global licensing agreement with Novartis Animal Health.

Page 2 of 2

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity	Name of entity
IMUGENE LIMITED
ABN 99 009 179 551	Quarter ended (“current quarter”)
99 009 179 551	30 June 2011

Consolidated statement of cash flows

Cash flows related to operating activities 1.1 Receipts from customers 1.2 Payments for (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital 1.3 Dividends received 1.4 Interest and other items of a similar nature received 1.5 Interest and other costs of finance paid 1.6 Income taxes paid 1.7 Other (provide details if material) R&D Rebate EMDG Grant Licence & Research Fees Net operating cash flows	Current quarter $A’000	Year to date (12 months) $A’000
	- (87) - (161) - (238) - 1 - - - 49 473	- (435) - (357) - (815) - 12 - - 301 76 2,463
	37	1,245

• See chapter 19 for defined terms.

Appendix 4C Page 1

17/12/2010

Appendix 4C Quarterly report for entities admitted on the basis of commitments

	Current quarter $A’000	Year to date (12 months) $A’000
1.8 Net operating cash flows (carried forward)	37	1,245
Cash flows related to investing activities 1.9 Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.10 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Other (provide details if material) Net investing cash flows 1.14 Total operating and investing cash flows	- - - - - - - - - - - - -	- - - - - - - - - - - - -
	-	-
	37	1,245
Cash flows related to financing activities 1.15 Proceeds from issues of shares, options, etc. 1.16 Proceeds from sale of forfeited shares 1.17 Proceeds from borrowings 1.18 Repayment of borrowings 1.19 Dividends paid 1.20 Other (provide details if material) Net financing cash flows	- - - - - -	- - - - - -
	-	-
Net increase (decrease) in cash held 1.21 Cash at beginning of quarter/year to date 1.22 Exchange rate adjustments to item 1.20 1.23 Cash at end of quarter	37 1,929 (60)	1,245 793 (133)
	1,906	1,906

• See chapter 19 for defined terms.

Appendix 4C Page 2

17/12/2010

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

1.24 Aggregate amount of payments to the parties included in item 1.2 1.25 Aggregate amount of loans to the parties included in item 1.11	Current quarter $A'000
	(87)
	-

• 1.26 Explanation necessary for an understanding of the transactions (i) Executive salaries, consulting fees and superannuation entitlements (ii) Non-executive director fees (iii) Rent

Non-cash financing and investing activities

• 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

None

• 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

None

Financing facilities available

Add notes as necessary for an understanding of the position.

3.1 Loan facilities 3.2 Credit standby arrangements	Amount available $A’000	Amount used $A’000
	Nil	N/A
	Nil	N/A

• See chapter 19 for defined terms.

Appendix 4C Page 3

17/12/2010

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash
Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter $A’000	Previous quarter $A’000
4.1 Cash on hand and at bank 4.2 Deposits at call 4.3 Bank overdraft 4.4 Other (provide details)	1,899	1,922
	7	7
	-	-
	-	-
Total: cash at end of quarter(item 1.23)	1,906	1,929

Acquisitions and disposals of business entities

5.1 Name of entity 5.2 Place of incorporation or registration 5.3 Consideration for acquisition or disposal 5.4 Total net assets 5.5 Nature of business	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
	N/A	N/A
	N/A	N/A
	N/A	N/A
	N/A	N/A
	N/A	N/A

Compliance statement

• 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

• 2 This statement does / ~~does not*~~ (delete one) give a true and fair view of the matters disclosed.

Sign here: ............................................................ Date: 28[th] July 2011 ~~(Director/~~ Company secretary)

Print name: Julie Foster

• See chapter 19 for defined terms.

Appendix 4C Page 4

17/12/2010

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Notes

1. The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.

3. Accounting Standards. ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

• See chapter 19 for defined terms.

Appendix 4C Page 5

17/12/2010